Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers
Epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC). Over the last 2 decades, the prognosis of HER2-positive metastati...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-05-01
|
| Series: | Cancer Control |
| Online Access: | https://doi.org/10.1177/10732748221106267 |
| _version_ | 1828347696254025728 |
|---|---|
| author | Alessandro Rizzo MD Antonio Cusmai MD Raffaella Massafra PhD Samantha Bove PhD Maria Colomba Comes PhD Annarita Fanizzi PhD Gennaro Gadaleta-Caldarola MD Donato Oreste MD Alfredo Zito MD Francesco Giotta MD Vito Lorusso MD Gennaro Palmiotti MD |
| author_facet | Alessandro Rizzo MD Antonio Cusmai MD Raffaella Massafra PhD Samantha Bove PhD Maria Colomba Comes PhD Annarita Fanizzi PhD Gennaro Gadaleta-Caldarola MD Donato Oreste MD Alfredo Zito MD Francesco Giotta MD Vito Lorusso MD Gennaro Palmiotti MD |
| author_sort | Alessandro Rizzo MD |
| collection | DOAJ |
| description | Epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC). Over the last 2 decades, the prognosis of HER2-positive metastatic BC patients has improved due to the introduction of anti-HER2 agents including trastuzumab and novel, emerging drugs and combinations such as trastuzumab deruxtecan and tucatinib – trastuzumab - capecitabine. Herein, we provide a critical overview of current clinical recommendations and emerging treatment options for metastatic HER2-positive BC, especially focusing on recently presented and published clinical trials in this setting. |
| first_indexed | 2024-04-14T00:44:07Z |
| format | Article |
| id | doaj.art-360c03889f5c4df8bfe1bc8d24c80f02 |
| institution | Directory Open Access Journal |
| issn | 1073-2748 |
| language | English |
| last_indexed | 2024-04-14T00:44:07Z |
| publishDate | 2022-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cancer Control |
| spelling | doaj.art-360c03889f5c4df8bfe1bc8d24c80f022022-12-22T02:22:05ZengSAGE PublishingCancer Control1073-27482022-05-012910.1177/10732748221106267Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New FrontiersAlessandro Rizzo MDAntonio Cusmai MDRaffaella Massafra PhDSamantha Bove PhDMaria Colomba Comes PhDAnnarita Fanizzi PhDGennaro Gadaleta-Caldarola MDDonato Oreste MDAlfredo Zito MDFrancesco Giotta MDVito Lorusso MDGennaro Palmiotti MDEpidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC). Over the last 2 decades, the prognosis of HER2-positive metastatic BC patients has improved due to the introduction of anti-HER2 agents including trastuzumab and novel, emerging drugs and combinations such as trastuzumab deruxtecan and tucatinib – trastuzumab - capecitabine. Herein, we provide a critical overview of current clinical recommendations and emerging treatment options for metastatic HER2-positive BC, especially focusing on recently presented and published clinical trials in this setting.https://doi.org/10.1177/10732748221106267 |
| spellingShingle | Alessandro Rizzo MD Antonio Cusmai MD Raffaella Massafra PhD Samantha Bove PhD Maria Colomba Comes PhD Annarita Fanizzi PhD Gennaro Gadaleta-Caldarola MD Donato Oreste MD Alfredo Zito MD Francesco Giotta MD Vito Lorusso MD Gennaro Palmiotti MD Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers Cancer Control |
| title | Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers |
| title_full | Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers |
| title_fullStr | Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers |
| title_full_unstemmed | Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers |
| title_short | Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers |
| title_sort | systemic treatments for metastatic human epidermal growth factor receptor 2 positive breast cancer old certainties and new frontiers |
| url | https://doi.org/10.1177/10732748221106267 |
| work_keys_str_mv | AT alessandrorizzomd systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers AT antoniocusmaimd systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers AT raffaellamassafraphd systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers AT samanthabovephd systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers AT mariacolombacomesphd systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers AT annaritafanizziphd systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers AT gennarogadaletacaldarolamd systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers AT donatoorestemd systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers AT alfredozitomd systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers AT francescogiottamd systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers AT vitolorussomd systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers AT gennaropalmiottimd systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers |